Login to Your Account



More Bad News for XenoPort: XP13512 Fails Migraine Study

By Trista Morrison


Thursday, July 8, 2010
Less than five months after the FDA handed XenoPort Inc. and partner GlaxoSmithKline plc an unexpected complete response letter for gabapentin enacarbil in restless legs syndrome (RLS), the drug failed a Phase IIb trial in migraine prevention. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription